(RTTNews) - Stock of NovoCure Limited (NVCR) is rising about 34 percent during Thursday morning trading following the U.S. FDA approval of Optune Pax for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.
The company's shares are currently trading at $14.17 on the Nasdaq, up 34.73 percent. The stock opened at $13.34 and has climbed as high as $14.96 so far in today's session. Over the past year, it has traded in a range of $9.82 to $22.95.
The approval was based on the Phase 3 PANOVA-3 trial, which demonstrated a statistically significant improvement in overall survival and delayed pain progression compared to chemotherapy alone.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
